- About Us
- Media Release
- Our Clients
- Media Mentions
- Subscription Model
- Contact Us
According to a new report, published by KBV research, The Global Actinic Keratosis Treatment Market size is expected to reach $8 billion by 2028, rising at a market growth of 4.4% CAGR during the forecast period.
The Nucleoside Metabolic Inhibitor segment acquired maximum revenue share in the Global Actinic Keratosis Treatment Market by Drug Class in 2021 thereby, achieving a market value of $2.6 billion by 2028. The success of Efudex, Carac, and fluroplex on the market is credited with spurring the development of nucleoside metabolic inhibitors. In addition, the category has grown owing to greater knowledge of actinic keratosis diagnosis and treatment.
The Surgery segment has shown the growth rate of 4.1 % during (2022 - 2028). Due to the higher accessibility of cryotherapy for the therapy of actinic keratosis, the surgery segment is projected to continue its dominance throughout the forecast period. In this procedure, the doctors cool the AK with liquid nitrogen. Abnormal tissue is selectively frozen and destroyed with liquid nitrogen. After a few days of irritation and perhaps blistering, the area recovers to its natural state. The doctor might utilize cryotherapy if patients have one or two AKs.
The Hospitals segment is leading the Global Actinic Keratosis Treatment Market by End-use in 2021 thereby, achieving a market value of $2.6 billion by 2028. This is related to elements including the accessibility of treatment rates, the presence of medical facilities, and the rise in photodynamic therapy treatments carried out in hospitals. A variety of prescription drugs are available for use during photodynamic treatment. It is possible to treat mild to moderately dense actinic keratosis on the upper arms, scalp, and face with prescription medications in hospitals.
The North America market dominated the Global Actinic Keratosis Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3 billion by 2028.The Europe market is exhibiting a CAGR of 4.1% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 5.2% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.
By Drug Class